Regeneron shares plunge after mixed COPD drug trial results

Regeneron shares fell nearly 19% after its experimental COPD drug, itepekimab, developed with Sanofi, showed mixed results in Phase 3 trials; the AERIFY-1 study demonstrated a 27% reduction in flare-ups, but AERIFY-2 failed to meet its primary endpoint. Lower-than-expected exacerbation rates, potentially linked to COVID-19 enrollment impacts, affected both trials, casting doubt on the drug's regulatory path and delaying hopes for a significant revenue stream, with projected peak sales potentially reaching $5 billion. Sanofi shares also declined around 5.5% following the announcement.

Analysis

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) shares plummeted nearly 19% after its experimental COPD drug, itepekimab, co-developed with Sanofi SA (NYSE:SNY), yielded mixed results in two Phase 3 trials, significantly clouding its regulatory prospects and delaying a potential major revenue stream. The AERIFY-1 study showed a 27% reduction in moderate or severe flare-ups over 52 weeks in former smokers with COPD, but the AERIFY-2 trial failed to meet its primary endpoint. Both companies indicated that lower-than-expected exacerbation rates, possibly due to reduced respiratory infection exposure during COVID-19 pandemic-era enrollment, impacted the trials. This outcome jeopardizes a drug once projected to achieve peak sales of $5 billion, leading to a commensurate c. 5.5% decline in Sanofi's US-listed shares. The event carries a strongly negative sentiment (overall score: -0.75; REGN: -0.9; SNY: -0.7) and a significant market impact score of 0.7, reflecting the substantial disappointment and uncertainty introduced by these trial results.

Key Decisions for Investors

• Investors holding Regeneron should closely monitor communications regarding regulatory discussions and any revised development or commercialization strategy for itepekimab, given the substantial stock impact and heightened uncertainty.
• For Sanofi investors, the c. 5.5% share decline suggests a more moderate, though still negative, impact; assess the drug's contribution to Sanofi's diversified pipeline and overall revenue outlook.
• Consider the implications of these trial setbacks for both companies' future R&D productivity and pipeline valuation, particularly for assets with high peak sales forecasts that may face similar challenges related to trial design or external factors like pandemic effects.